Optimizing Therapy for Patients Radioactive Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC) - Episode 12

Exploring Real-World Evidence Presented at ATA 2023

, , , ,

Medical professionals discuss the recently published real-world evidence presented at the American Thyroid Association 2023 Conference.

EP. 1: Differentiated Thyroid Cancer: Examining Key Epidemiological Trends
EP. 2: Exploring Incidence and Histology of Differentiated Thyroid Cancer
EP. 3: Determining Prognosis for Patients with Differentiated Thyroid Cancer
EP. 4: Predisposition for Patients Developing DTC: Age and Gender
EP. 5: The Role of Molecular Diagnostics in Real-World DTC Management
EP. 6: Employing Liquid Biopsies and ctDNA in DTC Diagnostic Strategies
EP. 7: The Importance of Thyroidectomy in DTC Patient Care
EP. 8: Post-Thyroidectomy Management: Thyroid Hormone Replacement and TSH Suppression
EP. 9: Identifying RAI-Refractory Disease: A Key Aspect of DTC Management
EP. 10: SELECT Trial & DECISION Trial Outcomes and Lessons Learned
EP. 11: Determining Which DTC Patients May Benefit from Systemic Therapy
Now Viewing
EP. 12: Exploring Real-World Evidence Presented at ATA 2023
EP. 13: Understanding the Impact of COSMIC-311 and Sequencing in DTC
EP. 14: Toxicity Profiles for DTC Guidelines Therapies
EP. 15: Addressing Unmet Needs and Challenges in RAI-R-DTC Treatment
EP. 16: Neoadjuvant Approach in RAI-R-DTC
EP. 17: Phase 2 ATLEP Trial Results
EP. 18: Reflecting on Differentiated Thyroid Cancer: Final Insights